Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia
Sponsored by Liaquat University of Medical & Health Sciences
About this trial
Last updated 2 years ago
Study ID
88_18.01.2023_QuercetinFit
Status
Completed
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18 to 75 Years
All Sexes
Trial Timing
Ended 2 years ago
What is this trial about?
Uric acid, a metabolic byproduct of purine degradation in humans, is a known risk factor for conditions such as gout and type 2 diabetes. Research has shown that supplementation with quercetin can significantly reduce plasma uric acid levels in individuals with mild hyperuricemia, potentially mitigating these associated risks.
What are the participation requirements?
Inclusion Criteria
* Aged between 18 and 75 years.
* Diagnosed with obesity.
* Diagnosed with hypercholesterolemia.
* With or without moderate hyperuricemia (serum uric acid ≥ 8 mg/dL).
* No restrictions on BMI, alcohol consumption, or smoking habits.
Exclusion Criteria
* Current use of uric acid-lowering medications (e.g., allopurinol, febuxostat).
* Diagnosed with oncological diseases.
* Diagnosed with neurological diseases.
* Diagnosed with inflammatory bowel diseases.